Nantong Jinghua Pharmaceutical Co Ltd (SHE:002349) — Market Cap & Net Worth
Market Cap & Net Worth: Nantong Jinghua Pharmaceutical Co Ltd (002349)
Nantong Jinghua Pharmaceutical Co Ltd (SHE:002349) has a market capitalization of $976.61 Million (CN¥6.67 Billion) as of September 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #9043 globally and #2211 in its home market, demonstrating a -13.28% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nantong Jinghua Pharmaceutical Co Ltd's stock price CN¥8.03 by its total outstanding shares 831128308 (831.13 Million). Also see balance sheet size of Nantong Jinghua Pharmaceutical Co Ltd for a full breakdown of the balance sheet.
Nantong Jinghua Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Nantong Jinghua Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.49 Billion to $976.61 Million (-1.93% CAGR). Also see how efficiently does Nantong Jinghua Pharmaceutical Co Ltd generate cash for how efficiently the company converts equity into cash flow.
Nantong Jinghua Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nantong Jinghua Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest Nantong Jinghua Pharmaceutical Co Ltd stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.60x
Nantong Jinghua Pharmaceutical Co Ltd's market cap is 0.60 times its annual revenue
Latest Price to Earnings (P/E) Ratio
4.03x
Nantong Jinghua Pharmaceutical Co Ltd's market cap is 4.03 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.16 Billion | $881.49 Million | $165.03 Million | 1.32x | 7.06x |
| 2017 | $884.40 Million | $1.12 Billion | $175.32 Million | 0.79x | 5.04x |
| 2018 | $668.44 Million | $1.35 Billion | $229.67 Million | 0.49x | 2.91x |
| 2019 | $526.86 Million | $1.16 Billion | -$393.62 Million | 0.46x | N/A |
| 2020 | $576.25 Million | $1.28 Billion | $110.99 Million | 0.45x | 5.19x |
| 2021 | $1.34 Billion | $1.36 Billion | $160.70 Million | 0.99x | 8.33x |
| 2022 | $1.44 Billion | $1.57 Billion | $212.23 Million | 0.91x | 6.78x |
| 2023 | $1.06 Billion | $1.51 Billion | $247.70 Million | 0.70x | 4.30x |
| 2024 | $930.39 Million | $1.40 Billion | $212.65 Million | 0.66x | 4.38x |
| 2025 | $882.96 Million | $1.46 Billion | $219.28 Million | 0.60x | 4.03x |
Competitor Companies of 002349 by Market Capitalization
Companies near Nantong Jinghua Pharmaceutical Co Ltd in the global market cap rankings as of September 19, 2026. Review Nantong Jinghua Pharmaceutical Co Ltd tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Nantong Jinghua Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #520 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #619 globally with a market cap of $44.48 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #637 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Haleon plc (NYSE:HLN): Ranked #665 globally with a market cap of $41.22 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #520 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #619 | GALDERMA GROUP AG | NYSE:GALDY | $44.48 Billion | $38.15 |
| #637 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.10 |
| #665 | Haleon plc | NYSE:HLN | $41.22 Billion | $9.36 |
Nantong Jinghua Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Nantong Jinghua Pharmaceutical Co Ltd's market cap moved from $1.49 Billion to $ 976.61 Million, with a yearly change of -1.93%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥976.61 Million | +10.61% |
| 2025 | CN¥882.96 Million | -5.10% |
| 2024 | CN¥930.39 Million | -12.64% |
| 2023 | CN¥1.06 Billion | -25.96% |
| 2022 | CN¥1.44 Billion | +7.51% |
| 2021 | CN¥1.34 Billion | +132.17% |
| 2020 | CN¥576.25 Million | +9.37% |
| 2019 | CN¥526.86 Million | -21.18% |
| 2018 | CN¥668.44 Million | -24.42% |
| 2017 | CN¥884.40 Million | -24.06% |
| 2016 | CN¥1.16 Billion | -21.70% |
| 2015 | CN¥1.49 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Nantong Jinghua Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $976.61 Million USD |
| MoneyControl | $976.61 Million USD |
| MarketWatch | $976.61 Million USD |
| marketcap.company | $976.61 Million USD |
| Reuters | $976.61 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nantong Jinghua Pharmaceutical Co Ltd
Jinghua Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China and internationally. The company offers active pharmaceutical ingredients (APIs) and intermediates, chemical and pharmaceutical intermediates, Chinese medicinal herbs and materials, health products, and Western medicine products. It also pr… Read more